Although the existing clinical guidelines recommend ticagrel or prasugrel as the first choice for patients undergoing percutaneous coronary intervention, considering that the use of ticagrel and prasugrel will increase the risk of bleeding in patients with ACS, clopidogrel is still the first choice for doctors and maintains the second largest prescription drug in the world.
正在翻译中..